CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma

被引：8

作者：

Tamer L. ^{[1
,6
]}

Ercan B. ^{[1
]}

Ercan S. ^{[2
]}

Ateş N. ^{[3
]}

Ateş C. ^{[5
]}

Öcal K. ^{[4
]}

Dirlik M. ^{[4
]}

Aydin S. ^{[4
]}

Atik U. ^{[1
]}

机构：

[1] Department of Biochemistry, Mersin University

[2] Department of Bioistatistics, Mersin University

[3] Department of Medical Biology and Genetics, Mersin University

[4] Department of General Surgery, Mersin University

[5] Department of General Surgery, Kocaeli University

[6] Mersin University, Medical Faculty, Department of Biochemistry, 33079, Mersin

来源：

International Journal of Gastrointestinal Cancer | 2006年 / 37卷 / 1期

关键词：

CYP2C19; Gastric and colorectal carcinomas; Polymorphism;

D O I：

10.1385/IJGC:37:1:1

中图分类号：

学科分类号：

摘要：

Background: It has been reported that up to 80% of human cancers arise as a consequence of environmental exposure and host susceptibility factors. Environmental carcinogens are predominantly metabolized by the cytochrome P450 (CYP) superfamily of drug- or xenobiotic-metabolizing enzymes. Genetic variations in these enzymes affect individuals' susceptibility to carcinogens. Aim of the study: The aim of this study was to evaluate the relationship between CYP2C19 polymorphism and susceptibility to these cancers by means of CYP2C19 genotyping among Turkish subjects. Methods: DNAof subjects were isolated from leukocytes by high pure template preparation kit (Roche Diagnostics, GmbH, Mannheim, Germany) and genotypes were detected by LightCycler CYP2C19 Mutation Detection Kit by real-time PCR with LightCycler instrument (Roche Diagnostics, cat. no. 3113914). Results: Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively). Conclusion: Although the frequency of CYP2C19*2 heterozygote genotype is high in our patients with gastric and colorectal carcinoma, there is no the relationship between CYP2C19 polymorphism and susceptibility to these cancer. © Copyright 2006 by Humana Press Inc. All rights of any nature whatsoever reserved.

引用

页码：1 / 5

页数：4

共 17 条

[11] Katoh T., Boissy R., Nagata N., Et al., Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma, Int J Cancer, 85, pp. 46-49, (2000)
[12] Suzuki S., Muroishi Y., Nakanishi I., Oda Y., Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer, J Gastroenterol, 39, pp. 220-230, (2004)
[13] Tanaka E., Update: Genetic polymorphism of drug metabolizing enzymes in humans, J Clin Pharm Ther, 24, pp. 323-329, (1999)
[14] Wadelius M., Autrup J.L., Stubbins M.J., Et al., Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer, Pharmacogenetics, 9, pp. 333-340, (1999)
[15] Roddam P.L., Rollinson S., Kane E., Et al., Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia, Pharmacogenetic, 10, pp. 605-615, (2000)
[16] Sachse C., Smith G., Wilkie M.J., Et al., A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer, Carcinogenesis, 23, pp. 1839-1849, (2002)
[17] Chau T.K., Marakami S., Kawai B., Nasu K., Kubota T., Ohnishi A., Genotype analysis of the CYP2C19 gene in HCVseropositive patients with cirrhosis and hepatocellular carcinoma, Life Sci, 67, pp. 1719-1724, (2000)

← 1 2 →